Loading
Life sciences · Journal article
Vascular Biology · September 21, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
The tumor microenvironment (TME) is a dynamic and complex ecosystem in which endothelial cells (ECs) play a central role beyond their traditional function as passive vascular conduits. Increasing evidence indicates that tumor-associated endothelial cells (TECs) undergo profound phenotypic and functional reprogramming, acquiring plasticity that enables them to adapt to hypoxic, inflammatory, and metabolic stresses. This plasticity encompasses a spectrum of states, including angiogenic activation, immune modulation, metabolic reprogramming, and endothelial-to-mesenchymal transition (EndMT). These transitions contribute to abnormal tumor vasculature, immune evasion, and therapeutic resistance. Advances in single-cell transcriptomics, spatial biology, and molecular pathology have revealed distinct endothelial subpopulations with unique biomarker signatures and functional roles within tumors. Importantly, TEC plasticity is now recognized as a key determinant of response to anti-angiogenic therapies and immune checkpoint inhibitors. This review synthesizes current knowledge on endothelial plasticity in cancer, proposes a conceptual framework for classifying TEC phenotypes, and highlights emerging biomarkers and therapeutic strategies targeting endothelial reprogramming. Understanding the dynamic nature of endothelial cells within the TME may enable the development of precision vascular therapies aimed at normalizing tumor vasculature and improving clinical outcomes.